Interpretation of the guidelines for neoadjuvant therapy of pancreatic cancer in China(2020 edition)
10.3760/cma.j.cn112139-20200708-00549-1
- VernacularTitle:《中国胰腺癌新辅助治疗指南（2020版）》解读
- Author:
Jiangdong QIU
1
;
Ruizhe ZHU
;
Hao CHEN
;
Taiping ZHANG
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院基本外科 100730
- Keywords:
Pancreatic neoplasms;
Combined modality therapy;
Neoadjuvant therapy;
Guidelines;
Interpretation
- From:
Chinese Journal of Surgery
2021;59(3):232-236
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is a highly malignant tumor in the digestive system.The role of neoadjuvant therapy in pancreatic cancer has been highlighted with the understanding of pancreatic cancer biological behavior and popularization of comprehensive treatment.Therefore,Study group of Pancreatic Surgery in China Society of Surgery of Chinese Medical Association and Pancreatic Disease Committee of China Research Hospital Association has formulated the guidelines for neoadjuvant therapy of pancreatic cancer in China(2020 edition).This guidelines elaborated key issues of the neoadjuvant therapy of pancreatic cancer,and provided reference for clinical practice.This article aims to interpret the guidelines about the preparation before neoadjuvant therapy, indication, regimen selection, therapeutic effect evaluation and surgery strategy, with further discussion about controversial issues of neoadjuvant therapy in pancreatic cancer.
